BRAF and familial papillary or follicular thyroid carcinoma: We also analyzed BRAF V600E mutation and clinicopathological characteristics in FNMTC and SNMTC and found that BRAF mutation in this study was not associated with gender, age, tumor size, inclusion, bilateral growth, thyroid nodular goiter, multifocal, lymph node metastasis, thyroid extradiffusion, iodine 131 treatment, T stage, and AJCC stage (p > 0.05) (Tables 7, 8).